139 related articles for article (PubMed ID: 23332108)
21. Heparin sensitivity and resistance in the neonate: an explanation.
Vieira A; Berry L; Ofosu F; Andrew M
Thromb Res; 1991 Jul; 63(1):85-98. PubMed ID: 1658964
[TBL] [Abstract][Full Text] [Related]
22. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
[TBL] [Abstract][Full Text] [Related]
23. Effect on thrombin generation of the "in vitro" addition of low-dose LMWH to plasma of healthy pregnant and nonpregnant women.
Rossetto V; Spiezia L; Dabrilli P; Gavasso S; Simioni P
Clin Appl Thromb Hemost; 2012 Jun; 18(3):331-3. PubMed ID: 22566703
[No Abstract] [Full Text] [Related]
24. Antithrombin-independent anticoagulation by hypersulfated low-molecular-weight heparin.
Fredenburgh JC; Anderson JA; Weitz JI
Trends Cardiovasc Med; 2002 Oct; 12(7):281-7. PubMed ID: 12458089
[TBL] [Abstract][Full Text] [Related]
25. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.
Morishima Y; Tanabe K; Terada Y; Hara T; Kunitada S
Thromb Haemost; 1997 Nov; 78(5):1366-71. PubMed ID: 9408021
[TBL] [Abstract][Full Text] [Related]
26. The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphate.
Ofosu FA; Blajchman MA; Modi GJ; Smith LM; Buchanan MR; Hirsh J
Br J Haematol; 1985 Aug; 60(4):695-704. PubMed ID: 2411283
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of extrinsic hemostasis activation by low-molecular-weight heparin.
Stief TW
Blood Coagul Fibrinolysis; 2006 Nov; 17(8):633-7. PubMed ID: 17102649
[TBL] [Abstract][Full Text] [Related]
28. Heparanase modulates heparinoids anticoagulant activities via non-enzymatic mechanisms.
Katz BZ; Muhl L; Zwang E; Ilan N; Herishanu Y; Deutsch V; Naparstek E; Vlodavsky I; Preissner KT
Thromb Haemost; 2007 Dec; 98(6):1193-9. PubMed ID: 18064313
[TBL] [Abstract][Full Text] [Related]
29. The evolution of oral anticoagulant therapy.
Dittus C; Ansell J
Prim Care; 2013 Mar; 40(1):109-34. PubMed ID: 23402464
[TBL] [Abstract][Full Text] [Related]
30. [Thrombin].
Camici M; Sagripanti A; Di Mitri R
Minerva Med; 2000; 91(5-6):105-12. PubMed ID: 11084844
[TBL] [Abstract][Full Text] [Related]
31. Effect of substrate and fibrin polymerization inhibitor on determination of plasma thrombin generation in vitro.
Lau A; Berry LR; Mitchell LG; Chan AK
Thromb Res; 2007; 119(6):667-77. PubMed ID: 16793122
[TBL] [Abstract][Full Text] [Related]
32. Effect of low molecular weight heparins and fondaparinux upon thrombin generation triggered by human pancreatic cancer cells BXPC3.
Gerotziafas GT; Galea V; Mbemba E; Sassi M; Roman MP; Khaterchi A; van Dreden P; Japcowitz M; Lotz JP; Bernaudin JF; Fareed J; Hatmi M; Elalamy I
Curr Vasc Pharmacol; 2014; 12(6):893-902. PubMed ID: 22724467
[TBL] [Abstract][Full Text] [Related]
33. Comparative anticoagulant activity and influence on thrombin generation of dextran derivatives and of a fucoidan fraction.
Mauray S; De Raucourt E; Chaubet F; Maïga-Revel O; Sternberg C; Fischer AM
J Biomater Sci Polym Ed; 1998; 9(4):373-87. PubMed ID: 9586785
[TBL] [Abstract][Full Text] [Related]
34. A comparison of pentosan polysulphate (SP54) and heparin. I: Mechanism of action on blood coagulation.
Fischer AM; Barrowcliffe TW; Thomas DP
Thromb Haemost; 1982 Apr; 47(2):104-8. PubMed ID: 6179182
[TBL] [Abstract][Full Text] [Related]
35. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro.
Gatt A; van Veen JJ; Woolley AM; Kitchen S; Cooper P; Makris M
Thromb Haemost; 2008 Aug; 100(2):350-5. PubMed ID: 18690358
[TBL] [Abstract][Full Text] [Related]
36. [Prenatal pharmacology of low molecular weight heparin and pentosan polysulfate].
Rainaut M; Forestier F; Daffos F; Fisher AM; Aiach M
J Mal Vasc; 1987; 12 Suppl B():119-22. PubMed ID: 2452225
[TBL] [Abstract][Full Text] [Related]
37. A new low molecular weight heparin fragment (PK 10169): in vitro and in vivo studies.
Vinazzer H; Woler M
Thromb Res; 1985 Oct; 40(2):135-46. PubMed ID: 3878009
[TBL] [Abstract][Full Text] [Related]
38. Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis.
Potze W; Arshad F; Adelmeijer J; Blokzijl H; van den Berg AP; Porte RJ; Lisman T
Br J Haematol; 2013 Dec; 163(5):666-73. PubMed ID: 24219333
[TBL] [Abstract][Full Text] [Related]
39. Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin.
Olson ST; Swanson R; Raub-Segall E; Bedsted T; Sadri M; Petitou M; Hérault JP; Herbert JM; Björk I
Thromb Haemost; 2004 Nov; 92(5):929-39. PubMed ID: 15543318
[TBL] [Abstract][Full Text] [Related]
40. Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation.
Young G; Yonekawa KE; Nakagawa PA; Blain RC; Lovejoy AE; Nugent DJ
Blood Coagul Fibrinolysis; 2007 Mar; 18(2):97-103. PubMed ID: 17287624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
